← Back to screener

AGIOS PHARMACEUTICALS, INC. AGIO

Rank #2129 · Nasdaq · $1.8B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
32.8
P/E
-5.2
P/B
1.65
ROE
-32.0%
Op. Margin
-1459.5%
Debt Ratio
11%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E -5.2x, P/B 1.65x. Ranks in the top 59% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -32.0%. Ranks in the top 90% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 11%. Ranks in the top 10% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★
Excellent

Revenue growth of 88.4% year over year. Ranks in the top 4% of the universe.

Growth is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2013$0.0B$-0.0B$-0.0B$-0.0B-76.2-563
2014$0.0B$-0.0B$-0.0B$-0.1B-91.6-481
2015–$-0.0B$-0.0B$-0.1B–-783
2016–$-0.1B$-0.1B$0.1B–219
2017$0.1B$-0.1B$-0.1B$0.4B-200.861
2018$0.1B$-0.2B$-0.2B$0.3B-287.669
2019$0.0B$-0.3B$-0.3B$0.4B-745.848
2020$0.1B$-0.4B$-0.3B$0.4B-384.046
2021–$-0.3B$-0.4B$0.7B–66
2022$0.0B$-0.3B$-0.3B$0.6B–23
2023$0.0B$-0.4B$1.6B$0.4B–35
2024$0.0B$-0.4B$-0.2B$1.3B-2732.110
2025$0.0B$-0.4B$-0.4B$1.1B-1459.511

← See the full screener